Xavier Leleu

2001–2026 年に発表

218
論文数
35,836
被引用数
94
h 指数
204
i10 指数

被引用数

Xavier Leleu の年別被引用数1988 年: 被引用 3 件1990 年: 被引用 1 件1993 年: 被引用 1 件1999 年: 被引用 2 件2001 年: 被引用 2 件2002 年: 被引用 10 件2003 年: 被引用 26 件2004 年: 被引用 21 件2005 年: 被引用 27 件2006 年: 被引用 33 件2007 年: 被引用 51 件2008 年: 被引用 97 件2009 年: 被引用 83 件2010 年: 被引用 117 件2011 年: 被引用 118 件2012 年: 被引用 137 件2013 年: 被引用 187 件2014 年: 被引用 201 件2015 年: 被引用 224 件2016 年: 被引用 207 件2017 年: 被引用 263 件2018 年: 被引用 266 件2019 年: 被引用 1,020 件2020 年: 被引用 1,377 件2021 年: 被引用 1,518 件2022 年: 被引用 1,254 件2023 年: 被引用 911 件2024 年: 被引用 1,642 件2025 年: 被引用 776 件2026 年: 被引用 21 件1989 年は被引用が無いため表示していません1991〜1992 年は被引用が無いため表示していません1994〜1998 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,891 件、この内訳の 24.3%中国: 引用元論文 896 件、この内訳の 7.6%イタリア: 引用元論文 792 件、この内訳の 6.7%フランス: 引用元論文 712 件、この内訳の 6%ドイツ: 引用元論文 693 件、この内訳の 5.8%イギリス: 引用元論文 644 件、この内訳の 5.4%スペイン: 引用元論文 608 件、この内訳の 5.1%オランダ: 引用元論文 405 件、この内訳の 3.4%カナダ: 引用元論文 393 件、この内訳の 3.3%ギリシャ: 引用元論文 355 件、この内訳の 3%オーストラリア: 引用元論文 302 件、この内訳の 2.6%ベルギー: 引用元論文 265 件、この内訳の 2.2%
0%24.3%その他 24.6%

分野

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology19.9%
  • Immunology and Microbiology3.9%
  • Engineering0.3%
  • Computer Science0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • その他0.9%

トピック

  • Multiple Myeloma Research and Treatments19.6%
  • Protein Degradation and Inhibitors8.8%
  • Peptidase Inhibition and Analysis4.7%
  • CAR-T cell therapy research3.9%
  • Chronic Lymphocytic Leukemia Research2.9%
  • Ubiquitin and proteasome pathways2.7%
  • その他57.4%

共著者

全論文

検索で開く
  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 被引用: 4,869

  2. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 被引用: 733

  3. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 被引用: 515

  4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 被引用: 953

  5. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 1,234

  6. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 987

  7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 被引用: 380

  8. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 363

  9. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn ほか 30 名 - The Lancet 2019 被引用: 636

  10. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  11. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2023 被引用: 124

  12. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 被引用: 275

  13. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tom Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi - Blood 2018 被引用: 420

  14. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 被引用: 324

  15. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 564

  16. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268

  17. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 被引用: 95

  18. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Surbhi Sidana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L. Kaufman - The Lancet Oncology 2024 被引用: 119

  19. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 110

  20. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 179

  21. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , - The Lancet 2020 被引用: 422

  22. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet Oncology 2021 被引用: 175

  23. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 535

  24. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    著者: , , , , , , , , , - Blood Advances 2023 被引用: 94